Skip to Main Content

Try STAT+ TODAY

Congress

Most Read

Pharmalot Ed Silverman

Wyden wants details on Amgen’s U.S. taxes as part of expanding probe into pharma practices

Politics Rachel Cohrs

Here’s who Democrats’ drug pricing bill will actually help

Politics Rachel Cohrs

In a massive victory for Democrats, Medicare is poised to negotiate drug prices

Politics Rachel Cohrs

Democrats dramatically narrow their ambitions for lowering insulin costs

Politics Rachel Cohrs

Democrats will have to limit their drug pricing reforms to Medicare to comply with Senate rules

Politics Rachel Cohrs

The glaring health equity gap in Democrats’ drug pricing plan

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: The last-minute push for drug pricing reform, Alnylam’s success, and Sarepta’s gamble

First Opinion David Blumenthal

Keeping climate provisions in the budget reconciliation act is a key step toward protecting Americans’ health

All Coverage

Politics Rachel Cohrs

Unpacking the drug pricing policies that Congress just approved

Health Care Inc. Bob Herman

Private equity’s latest fixation & the ACA subsidy spigot

advertisement

Politics Rachel Cohrs

Cancer patient who devoted six years to drug pricing reform isn’t done yet

Politics Rachel Cohrs

In a momentous vote for Pelosi, House sends drug pricing reforms to President Biden’s desk

D.C. Diagnosis Elissa Welle

Democrats’ TGIF moment, pathologists defend their turf, & Biogen’s back at the FDA’s doorstep

Matt's Take Matthew Herper

The Senate’s drug pricing bill is an inevitable solution. It will still have plenty of unintended consequences

Health Care Inc. Bob Herman

A lobbying frenzy over surprise billing, employer dialysis questions, and a big broker throwdown

D.C. Diagnosis Edward Chen

A chaotic sprint to lower insulin prices and AIDS activists go after Biden on monkeypox

D.C. Diagnosis Rachel Cohrs

The view on drug pricing from Wall Street, a pharma-friendly Dem holds firm, and what’s next for a big telehealth bill

Pharmalot Ed Silverman

Wyden says Merck and Abbott aren’t cooperating with probe into pharma tax practices

Politics Nicholas Florko

Senators demand answers about federal prisons’ scant use of Covid therapeutics

Politics Rachel Cohrs

‘What can we do?’: Pharma lobbyists face their biggest test in a decade, as Democrats barrel toward a vote on drug pricing

First Opinion Craig Garthwaite

Drug price controls are a dance with the devil: short-term savings will be overwhelmed by loss of innovation

Politics Nicholas Florko

Powerful Senate Democrat outlines ‘plenty’ more drug pricing reforms to follow Medicare negotiation

Health Care Rachel Cohrs

Virtual Event: Democrats’ Last Chance for Drug Pricing Reform?

D.C. Diagnosis Nicholas Florko

PhRMA and BIO descend on D.C. & unpacking the Senate’s FDA funding drama

Politics Nicholas Florko

The politics of passing a major FDA funding bill just got complicated

Politics Nicholas Florko

Durbin, Collins blast FDA for failure to ban certain synthetic e-cigarettes

Politics Rachel Cohrs

Here’s what Democrats changed in their latest drug pricing bill

Politics Rachel Cohrs

Democrats tweak their drug pricing plan in last-ditch effort to pass reforms

D.C. Diagnosis Rachel Cohrs

The unlikely crusader who’s winning the fight to lower hospital prices

First Opinion Cliff A. Megerian and Peter Pronovost

Now is not the time for Congress to further cut hospitals’ Medicare payments

Politics Rachel Cohrs

New Senate proposal to lower insulin prices would let drugmakers lock in their current profits

Politics Lev Facher

Congress is closer than ever to formally authorizing ARPA-H. But the details aren’t as final as they seem

First Opinion Carl Schmid

Congress: Fund PrEP to end the HIV epidemic